Dr. Winnie Mpanju-Shumbusho has more than 30 years experience in key senior leadership positions in health, public health, global health and international cooperation. She served as the World Health Organization’s Assistant Director General for HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases, World Health Organization until her retirement on 31 December 2015. She led WHO’s work in prevention, control, impact-mitigation, technical support to countries; and global partnerships to combat these diseases, thus contributing to achievement of the Millennium Development Goals. Her vision and leadership also ensured effective transition of the WHO’s HTM Cluster’s work from the MDG to the SDG framework.
Previously Dr. Mpanju-Shumbusho deputized the WHO ADG/HTM; and concurrently directed the WHO’s Office for Global Fund Partnership and Technical Cooperation, including WHO’s technical support to countries, that facilitated eligible countries’ access and utilisation of more than 10 billion USD from the Global Fund to Fight AIDS, Tuberculosis and Malaria and contribute to health systems strengthening.
Earlier she served as Director of the WHO’s HIV/AIDS and Sexually Transmitted Infections Programme.
She has also served as a member of various international boards, including the Global Fund Board, “Uniting to Combat Neglected Tropical Diseases”Board; WHO/UNICEF-UNDP-World Bank Special Programme for research and training in Tropical Diseases (TDR) Board; UNITAID Board and UNAIDS Programme Coordination Board and Tanzania National Urban Water Authority Board.
Prior to joining WHO, Dr Mpanju-Shumbusho was Director General of the Commonwealth Regional Health Community Secretariat for East, Central and Southern Africa (now known as the East, Central and Southern Africa Health Community Secretariat), where she spearheaded policies and mobilised political commitment, resources and partnerships to tackle the Region’s public health priorities. She also served as the Head of the University of Dar-es-salaam’s Department of Community Health; Senior Lecturer in Paediatrics & Child Health and Community Health; Chief Public Health Adviser to the Ministry of Health of Tanzania; and International Monitor of multi-country clinical trials for malaria drugs and vaccines on behalf WHO/TDR.
Dr. Mpanju-Shumbusho has won various leadership, humanitarian and academic awards, including the AHEAD Humanitarian Award; and she has published widely.
As a native of a malaria endemic country, Dr Mpanju-Shumbusho brings a multi-faceted perspective to the RBM Board, along with her unwavering commitment and resolve to end the scourge of malaria.
Mr. Daly brings a range of necessary and appropriate experience around advocacy, resource mobilization and connections to the Global Fund and major donors over the last 20 years, along with organizational leadership and authority.
As Deputy Director within Global Policy and Advocacy at the Foundation, he is responsible for HIV, TB, Malaria advocacy and Global Fund investments. This includes acting as relationship owner for the foundation’s engagement with the Global Fund as well as Board member representing Private Foundations.
Extensive experience in multilateral, international and national policy and advocacy, including as CEO of ICASO a global AIDS advocacy organization and network. Involved with the Global Fund to fight AIDS, TB and Malaria since its inception, including as the Alternate Board member for the Developed Country NGO delegation and as a member of various committees including the Finance and Audit Committee, and currently on the Strategy Committee. Extensive experience with the UN, with particular focus on HIV policy and programming, through involvement and leadership roles in most of the major global HIV initiatives, working groups and committees within UNAIDS and the UN General Assembly. Led major initiatives supporting advocacy in developing countries on HIV, TB and malaria.
Dr Pedro L. Alonso is the Director of the WHO Global Malaria Programme in Geneva, Switzerland. The Global Malaria Programme is responsible for the coordination of WHO’s global efforts to control and eliminate malaria and sets evidence-based norms, standards, policies and guidelines to support malaria-affected countries around the world.
A national of Spain, Dr Alonso has spent over 30 years in public health. His scientific research work has focused on key determinants of morbidity and mortality in the most vulnerable population groups. He has published over 300 articles in international peer-reviewed journals – primarily on malaria treatment, vaccine trials and preventive therapies – and has served on several national and international committees. He is particularly committed to capacity building of both institutions and individuals, primarily in Africa.
Prior to taking up the WHO position, Dr Alonso was Director of the Barcelona Institute for Global Health (ISGlobal) and Professor of Global Health at the University of Barcelona, and President of the Governing Board of the Manhiça Foundation and the Manhiça Health Research Centre in Mozambique.
Mr. Sy has extensive experience in leadership roles in the humanitarian sector, having previously served at a senior level with UNICEF, UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and other agencies for more than 25 years.
Before joining the IFRC – the world’s largest humanitarian network – Mr. Sy was UNICEF’s Director of Partnerships and Resource Development in New York. He has also served as UNICEF Regional Director for Eastern and Southern Africa and Global Emergency Coordinator for the Horn of Africa. From 2005 to 2008, Mr. Sy was Director, HIV/AIDS Practice with the United Nations Development Programme in New York. Before that, he worked with the Global Fund to Fight AIDS, Tuberculosis and Malaria as its Africa Regional Director and later as Director of Operational Partnerships and Country Support in Geneva.
Mr. Sy has also held the position of UNAIDS Representative in New York and Director of the New York Liaison Office. From 1988 to 1997, he served as Director of Health and Development Programmes with Environment and Development Action in the Third World in Dakar, Senegal.
Dr. Maha Barakat has held the post of Director General of the Health Authority Abu Dhabi since 2013. Previously, she was Co-Founder, Medical & Research Director and Consultant Endocrinologist at the Imperial College London Diabetes Centre (ICLDC) in Abu Dhabi, and Reader at Imperial College London. In 2013, she became a visiting Professor at Imperial College London.
She is a member of the Social Development Committee of the Executive Council of the Government of Abu Dhabi, and Board member of several Government of Abu Dhabi-related entities including the Board of Trustees of the Family Development Foundation, the Abu Dhabi Quality and Conformity Council, and the Statistics Centre Abu Dhabi.
As part of her role within the Health Authority, in addition to the fight against lifestyle-related disease, Dr. Barakat has supported several public health eradication campaigns against communicable disease both within the UAE and internationally, including Africa and the Indian subcontinent.
For her work to the community in the UAE, Dr. Barakat was appointed an Officer of the Order of the British Empire (OBE) in 2010, was awarded the Abu Dhabi Prize in 2011, and given the Imperial College Medal in 2013.
Simon Bland has over thirty years of experience in global development, most of this living in Asia, the Pacific and in Africa. His early career was focused on marine sciences and natural resources management, later moving into development economics and management. Over the last ten years he has maintained a strong focus on global health. Simon presently leads the UNAIDS New York Office and was instrumental in helping formulate the SDG and specifically Goal 3 and its targets.
Before joining UNAIDS Mr. Bland was a senior civil servant in the United Kingdom’s Department for International Development (DFID) and, most recently, headed their Global Funds Department. He was responsible for the United Kingdom’s policies, programmes, financial management and shareholder relations with Global Funds and Innovative Finance in health and education. He represented the United Kingdom on the Boards of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), the GAVI Alliance, UNITAID and the Global Partnership for Education.
From September 2011 to June 2013, Mr. Bland was Chair of the Board of the Global Fund and oversaw a substantial transformation culminating with the introduction of its new funding model and strengthened partnership approach. Mr Bland is a member of the National Academies Forum on Public Private Partnerships and sits on a number of Boards in the UK an USA. In 2013 he was made A Commander of the British Empire in the Queen’s Birthday List for services to global health.
Minister of Health of the Republic of Senegal since 2012, Prof Awa Marie Coll-Seck is member of the FP2020 Reference Group, the National Academy of Pharmacy of France, the Board of Every Women Every Child, the Board of Cheikh Zaïd University (Morocco) and of the Global Financing Facility for maternal and child health’s Investisor Group. She also represents West Africa and Central in the Global Fund’s Board.
Professor of infectious diseases and bacteriology, she has been previously Executive Director of the RBM Partnership for 8 years and served successively as Director of the Department of Policy, Strategy and Research and Department of Country and Regional Support of the UNAIDS from 1996 to 2001.
Dr. Coll Seck received during her career several awards and distinctions.
Paulo Gomes is a global business leader, active environmentalist and a key political actor in Guinea Bissau. His constant search for how to reposition the country and help it become stable and prosperous is what led him to initiate the Bissau Economic Forum now in its second edition.
The forum is a bi-annual discussion and investment forum on cooperation and the economic transformation of the country with all stakeholders from civil society, private sector and the government in order to attract foreign investment as well as create employment. In addition to the acute knowledge of the politics and policies of Africa that he developed through his political engagement, support to several governments and as an Executive Director of the World Bank. Paulo Gomes has founded Paulo Gomes and Partners a strategic advisory and investment firm focused on a high level limited set and sectors of clients with advice and tailored made solutions.
Paulo Gomes has a strong network of alliances with private equity and sovereign funds as well as family offices. Paulo Gomes and Partners is the natural outcome of years advising governments and businesses on strategic investments as well as years on serving on boards of firms such as AFIG, Asky Airlines and Ecobank. A founder of the South East Asia-Africa Chamber of Commerce and Chairman of the Advisory Board his business reach touched all continents and interests, Paulo is also a senior advisor to PIL Group. Yet for Paulo, business cannot be at the expense of human development and the environment. Through his engagement with several organizations, including the Green Climate Fund, as a member of the Bio Guiné Foundation, and as a contributor to the African Green Revolution Forum, he has demonstrated global leadership on environmental protection. In Guinea Bissau, he is joining rhetoric to practice by creating an experimental center that brings together island communities, national and foreign researchers around training and creating green jobs in the protected Bijagós islands.
In his home country Guinea Bissau, Paulo has initiated the Benten Institute, a non-partisan think tank established to guide and advise on the development of Guinea Bissau. The Institute has received wide support within and outside Guinea Bissau, and has been commended throughout the continent at its inaugural event, the Bissau Economic Forum held in February 2013. Paulo holds a Bachelors degree in Economics from ILERI, Paris and a Masters Degree from Kennedy School of Government, Harvard University.
Dr. Mirta Roses Periago, from Argentina, is the Director Emeritus of the Pan American Health Organization (PAHO), founded in 1902, also Office for the Americas of the World Health Organization (WHO). She served as Director for two consecutive terms from 2003 to 2013 becoming the first woman to head the world’s oldest international public health organization and the first female WHO Regional Director.
She previously served two terms as Assistant Director of PAHO (1995-2003) responsible for the direct supervision of PAHO/WHO Representative Offices in the Americas, forming part of WHO’s Directors of Program Management Group (DPM) and the Global Program Management Group (GPMG), which she chaired for two periods. Dr. Roses has vast international experience in public health, having worked for almost three decades on behalf of the countries of the Americas, actively participating in global efforts in epidemic control, equity in health, social promotion, and health regulation.
She started her international career as coordinator of the Epidemiological Surveillance Unit of the Caribbean Epidemiology Center (CAREC) in Trinidad and Tobago (1984-1986), where she provided service to all the Caribbean countries, and as an epidemiologist in the Dominican Republic (1986-1987.) She served as PAHO/WHO Representative in the Dominican Republic (1988-1992) and in Bolivia (1992-1995).
Dr. Roses Periago has an extensive history of service in public health at the national level, working in epidemiology and health research in Argentina’s Ministry of Health (1977-1984) and in primary health care programs in the city of Buenos Aires (1974 1976.)
Dr. Roses has been Advisor to the High-Level Secretariat for the Earth Institute ALAS Initiative on Early Childhood Development (ECD) at the Earth Institute in Colombia University and chaired the Global Agenda Council on Chronic Diseases and Well-Being (GAC) of the World Economic Forum for the term of August 2010 through July 2011.
Currently she is a corresponding member of the National Academy of Medicine (Buenos Aires.), Special Envoy Sabin Vaccine Institute for the Global Network on NTDs, Board Member representing LAC at the Global Fund AIDS, Malaria, Tuberculosis and Board Member Roll Back Malaria, WHO SAG on Malaria eradication, Sasakawa Foundation SAG on Global leprosy elimination.
Dr. Kamwi convened the inaugural Elimination 8 Ministerial Initiative, which was established in 2009 as a platform for regional collaboration towards elimination in the SADC region. He is an expert in the field of malaria elimination, holding a PhD in Malariology, and began his career in malaria as the head of the malaria response in Namibia, prior to his appointment as Deputy Minister of Health, and then Minister of Health. While Minister of Health, he led an effort to secure both domestic and external resources for the health sector, greatly expanding Namibia’s response to HIV, TB, and malaria.
Dr. Kamwi has demonstrated commitment and leadership for malaria elimination in southern Africa, and was requested to continue to support the region as E8 Ambassador after his term in office. As E8 Ambassador, Dr. Kamwi supports diplomatic and strategic engagement by the Ministers of Health of SADC. Dr. Kamwi is a sought after advisor and speaker on various issues, and malaria in particular; he serves as a member of the UNITAID Expert Advisory Panel, as well as the WHO Regional Director’s independent advisory group.
Dr. Lal is Senior Advisor for Global Health and Innovation, Sun Pharma. With vast interest and knowledge of Discovery, Development, Delivery, and Diplomacy in biomedical sciences and public health Dr Altaf Lal has over three decades’ experience in malaria and infectious disease laboratory and field research, vaccinology, biotechnology, product safety, and health policy. He has strong leadership skills using science-based decision making, strategic thinking, and fostering teamwork approach.
Throughout his career Dr. Lal has worked towards building bilateral and multilateral partnerships, which has led to significant growth and collaborations at academic, institutional, industry and government levels. He has received FDA Commissioner’s Special Citation Award, Unit Citation Award, U.S. Department of Commerce, National Oceanic Atmospheric Administration, National Oceanic Service, James H. Nakano Citation, National Center for Infectious Disease (NICD), CDC, Outstanding Scientific Contribution to Public Health Award, NCID, CDC, Honor Award, NICD, CDC, Group Honor Award for Operational Research, NCID, CDC. He is recipient of the Life Time Achievement Award in 2016 and the Gugnani Oration Award in 2011 by the Indian Society of Malaria and other Communicable Diseases, Public Health Ambassador Award, NICD, Ministry of Health and Family Welfare, 2009, and HIV/AIDS Ambassador Award, Hyderabad University, 2007.
Previously, Dr. Lal served as the Director of FDA India Office; Technical Director, Decade of Vaccines Collaboration; Chief Executive Officer, Hilleman Laboratories, U.S. Health Attaché and Regional Representative for South Asia at the U.S. Embassy in India; Chief Malaria Vaccine Section at the Centers for Disease Control and Prevention (CDC), Atlanta, GA. Dr. Lal has published over 220 papers.
Mr. Nishimoto is a member of the Board of Sumitomo Chemical and responsible for the Health & Crop Sciences Sector. Sumitomo Chemical is one of Japan’s leading chemical companies with operations in five business sectors: Petrochemicals & Plastics, Energy & Functional Materials, IT-related Chemicals, Health & Crop Sciences and Pharmaceuticals.
Mr. Nishimoto joined Sumitomo Chemical in 1980 and has more than 20 years of extensive management experience and expertise in Health & Crop Sciences. He has served as Executive Vice President at Valent USA Corporation (Walnut Creek, CA), one of Sumitomo Chemical’s affiliates in Crop Protection business from 1998 to 2003. He became an Executive Officer in 2009, a Managing Executive Officer in 2011, a member of the Board (Representative Director) in 2013 and a Senior Managing Executive Officer of Sumitomo Chemical in 2015.
Since 2010, Mr. Nishimoto has supervised Global Crop Protection, Vector Control and Sectorial Planning. Since 2013, he has supervised all sector business including Environmental Health, Animal Nutrition and Pharmaceutical Chemicals (API and Intermediates). His mandate for Vector Control is to provide integrated technical solutions for disease prevention in a manner that maximizes lives saved, as part of Sumitomo Chemical’s commitment to CSR. Mr. Nishimoto has also served as a member of the Crop Protection Strategic Council, CropLife International since 2010 (Vice Chair from 2014), as the Vice President of Japan Crop Protection Association as well as a member of the Board of Advisors of Friends of the Global Fund, Japan since 2013 and as a member of the Board of Malaria No More Japan since 2016. He holds a B.A. in Economics with honors from Osaka University.
Dr. David Reddy has been CEO of Medicines for Malaria Venture since January 2011. Under his leadership, this not-for-profit research foundation has brought forward four new antimalarial drugs, broadened its malaria-drug pipeline to include 7 novel drugs in clinical development. In addition, it has received Board and donor endorsement of a 5-year strategy focused on developing new medicines to address the unmet needs of vulnerable populations most affected by malaria.
Prior to joining MMV, Dr. Reddy was a Vice President in the Global Product Strategy unit at F. Hoffman-La Roche Ltd, Basel Switzerland, where he served as Pandemic Taskforce Leader. Prior to that he was the Global Franchise Leader for HIV/AIDS at Roche, where he oversaw the successful development and introduction of enfuvirtide, the first HIV fusion inhibitor. He was also responsible for developing Roche’s HIV drug access policies and initiatives. His résumé includes over 20 years of ‘Pharma’ experience, including successful leadership of drug development teams, licensing and alliance management, product and disease area management, market analytics and business planning. His roles also included interfacing with governments, NGOs and patient advocacy groups around access to medicines for priority diseases.
Dr. Reddy holds a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand. His PhD thesis involved cloning the serotypic antigen for rotavirus and development of a recombinant rotavirus vaccine. He completed a post-doctoral fellowship at the Freidrich Miescher Institute in Basel, where he cloned and expressed developmentally-regulated brain-derived microtubule associated proteins
Professor Dr. Yongyuth Yuthavong is a former Deputy Prime Minister and former Minister of Science and Technology, Thailand and an outstanding Thai scientist with a particular interest in the broad issues of public policies, especially those concerning the application of science and technology for development – as well as human development in general.
Dr. Yongyuth spent a long career at Mahidol University, conducting research and teaching. He was appointed Professor of Biochemistry in 1983 and was honoured with the “Outstanding Scientist of Thailand” Award in 1984, from the Foundation for the Promotion of Science and Technology. During the same period, he was chosen as the Director of the National Centre for Genetic Engineering and Biotechnology (BIOTEC) from 1985 until 1989.
Dr. Yongyuth became the first President of Thailand’s National Science & Technology Development Agency (NSTDA) from 1992 until 1998 and in 2004, he received the Nikkei Asia Prize for Science, Technology and Innovation from the Nihon Keizai Shimbun, Japan, for his outstanding work on antimalarial drug targets, as well as the prestigious “Person of the Year” Award from Thailand’s National Identity Board. Dr. Yongyuth served as the Minister of Science and Technology from 2006 to 2008, when The Nation newspaper named him one of “the 35 most influential Thais over the past 35 years”. Dr. Yongyuth has since returned to his research career with BIOTEC, where he now heads a research group working on the development of new antimalarials.